Synonym
PF-5006739; PF 5006739; PF5006739.
IUPAC/Chemical Name
4-[4-(4-Fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-2-pyrimidinamine
InChi Key
XPWHRQHBPRSUAW-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H22FN7O/c23-16-3-1-15(2-4-16)20-21(19-5-9-25-22(24)27-19)30(14-26-20)18-6-10-29(11-7-18)13-17-8-12-31-28-17/h1-5,8-9,12,14,18H,6-7,10-11,13H2,(H2,24,25,27)
SMILES Code
NC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCN(CC5=NOC=C5)CC4)=N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM.
In vivo activity:
Similar to studies in DIO mice, PF-5006739 treatment (10 mg/kg/day, ZT10) did not affect body weight, feeding behaviour, or activity profiles in ob/ob mice, relative to vehicle-treated ob/ob mice (Fig. 5d, Supplementary Fig. S4). Yet once again, daily administration of PF-5006739 significantly improved blood glucose profiles during GTT (Fig. 5d). No difference in glucose clearance was observed in lean (NC-fed) C57Bl/6J mice treated with PF-5006739 relative to vehicle-treated mice (Supplementary Fig. S4).
Reference: Sci Rep. 2016 Jul 21;6:29983. https://pubmed.ncbi.nlm.nih.gov/27439882/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
71.0 |
169.20 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
419.46
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Cunningham PS, Ahern SA, Smith LC, da Silva Santos CS, Wager TT, Bechtold DA. Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in obesity. Sci Rep. 2016 Jul 21;6:29983. doi: 10.1038/srep29983. PMID: 27439882; PMCID: PMC4954991.
In vivo protocol:
Cunningham PS, Ahern SA, Smith LC, da Silva Santos CS, Wager TT, Bechtold DA. Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in obesity. Sci Rep. 2016 Jul 21;6:29983. doi: 10.1038/srep29983. PMID: 27439882; PMCID: PMC4954991.
1: Cunningham PS, Ahern SA, Smith LC, da Silva Santos CS, Wager TT, Bechtold DA.
Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in
obesity. Sci Rep. 2016 Jul 21;6:29983. doi: 10.1038/srep29983. PubMed PMID:
27439882; PubMed Central PMCID: PMC4954991.
2: Wager TT, Chandrasekaran RY, Bradley J, Rubitski D, Berke H, Mente S, Butler
T, Doran A, Chang C, Fisher K, Knafels J, Liu S, Ohren J, Marconi M, DeMarco G,
Sneed B, Walton K, Horton D, Rosado A, Mead A. Casein kinase 1δ/ε inhibitor
PF-5006739 attenuates opioid drug-seeking behavior. ACS Chem Neurosci. 2014 Dec
17;5(12):1253-65. doi: 10.1021/cn500201x. Epub 2014 Oct 28. PubMed PMID:
25299732.
